Most studies in CKD patients measuring the intact FGF23 assay found a decrease of FGF23 with the use of either sevelamer [124–126, 128], or lanthanum carbonate [129–131] in CKD stage 2–5 patients. This evidence concerns the gene FGF23 and chronic kidney disease.